Zepbound vs Wegovy: Which Is Right for You?

The short version, mom to mom

When I started digging into this, everyone in my group chat talked about Zepbound and Wegovy like they were the same shot with different labels. They're not. They're the two FDA-approved brand-name injections for weight loss, and there's finally a head-to-head trial that separates them: over 72 weeks, Zepbound produced meaningfully more weight loss than Wegovy and was declared superior on that measure¹. So if you only care about the bigger number, that's your answer.

But here's what actually happened when I tried to make this decision for real life: the number stopped being the whole story. Side effects, cost, breastfeeding and pregnancy timing, and a birth-control interaction that hits Zepbound but not Wegovy all crashed the party. If you're a mom weighing these, those belong in the same conversation as the efficacy headline.

One naming thing first, because it tripped me up: Zepbound and Wegovy are the brands approved for weight loss. The exact same two molecules are sold as Mounjaro (tirzepatide) and Ozempic (semaglutide) for type 2 diabetes. Same drugs, different brand and indication. If your friend "did great on Mounjaro," that's tirzepatide — the Zepbound molecule.

Boundary I hold myself to: I don't create accounts, enter medical info, or check out — this is education from the public funnel and published research, not medical advice. I checked every clinical claim below against FDA labels and published trials.

The head-to-head data (finally a real one)

For a long time these comparisons leaned on separate trials, which is a bit like arguing whose kid is taller from two different school photos. Now there's a direct one. SURMOUNT-5 randomized 751 adults with obesity to Zepbound or Wegovy for 72 weeks at their maximum tolerated doses. Mean weight change was −20.2% with tirzepatide versus −13.7% with semaglutide, and tirzepatide came out superior for both weight and waist-circumference reduction¹.

That tracks with each drug's own pivotal trial — semaglutide produced about 15% average weight loss in STEP 1², and tirzepatide about 20% at the top dose in SURMOUNT-1³ — so this isn't one weird study. The direction is consistent across the evidence.

The honest caveat I keep reminding myself of: "more on average" is a fact about groups, not about me. Plenty of women lose a lot on semaglutide, tolerate it better, or pay less for it. The trial tells you where the averages point, not where any single mom lands.

Side effects: same family, mostly during the dose climbs

Both are built on GLP-1 signaling (Zepbound adds a second target, GIP), so the side-effect profile rhymes. The gastrointestinal stuff — nausea, diarrhea, constipation, vomiting — is the most common with both, most of it is mild to moderate, and it clusters during the dose-escalation phase rather than at a stable maintenance dose¹. Neither one is reliably the "gentle" option; tolerance is personal. A good program titrates slowly and switches you if a molecule just doesn't sit right.

If the side-effect question is the one keeping you up, I wrote a whole practical rundown in managing GLP-1 side effects — what actually helped me and when it's a call-your-clinician moment.

Staying there: the maintenance question a mom actually asks

Weight loss that snaps back the second you stop isn't the goal, and this is where the mom lens earns its keep. Both drugs are studied as ongoing treatments. When semaglutide was stopped and switched to placebo, much of the lost weight came back⁴. Continuing tirzepatide, on the other hand, held the reduction where stopping did not⁵. If you might pause treatment for a pregnancy someday, "what happens when I stop, and how do I restart?" is a far more useful question than "which number is bigger?" I dug into that in what really happens when you stop a GLP-1.

Cost and access (the part that decided it for a lot of us)

Zepbound is frequently priced higher than Wegovy, which my budget noticed before my group chat did. Both manufacturers run savings programs, and real-world availability of each has swung with shortages. For most moms I know the practical driver isn't the trial — it's what insurance covers and what the out-of-pocket number is. One provider publishes both ladders side by side in plain dollars: Knownwell lists Zepbound from $299 in a vial against the Wegovy pen at $349, and bills the visit to insurance. Otherwise my cheapest-GLP-1 board and how much a GLP-1 really costs without insurance are where I'd start — price it before falling in love with a molecule, a mistake I made in the other order.

The mom-specific stuff a brand comparison skips

Two facts matter here that a straight efficacy chart leaves out completely:

• Birth control. The Zepbound label carries an explicit warning that oral hormonal contraceptives may become less effective, and it advises switching to a non-oral method or adding a barrier method around starting the drug and around each dose increase⁶. I went and read the Wegovy labeling myself afterwards, and it does not carry that specific warning. I was on the pill at the time, so for me this was not a footnote — it was a real, practical difference between the two.
• Breastfeeding and pregnancy timing. This is the one place the two genuinely part company. Wegovy's label asks you to stop at least two months before a planned pregnancy; Zepbound's sets no pre-pregnancy window and says to stop once a pregnancy is recognized. That "week per dose" figure everyone quotes is the half-life, not the instruction. Nursing is softer than either — the injectable labels don't tell you to stop, they record that there's no human-milk data and ask you to weigh it. My guide to GLP-1s while breastfeeding has the detail.

How I'd actually choose

The averages favor Zepbound, but averages aren't people. Tolerance, cost, what your insurance covers, whether you take the pill, and your pregnancy plans all feed a real decision — and a good program can switch molecules if the first one isn't your fit. If you're wondering whether a smaller starting dose is reasonable, see microdosing GLP-1s. Bring your history and your plans to a clinician and decide together — don't pick from a brand name.